Melanocortins have been previously shown to participate in the regulation of sodium homeostasis and vascular function, but here we show for the first time that pharmacological targeting of melanocortin receptors with a pan-agonist, NDP-α-MSH, possesses therapeutic efficacy in experimental hypertension. Here, NDP is linked to hypertensive disorder.